NCT03507842 - A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML. | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

High dose Cytarabine

High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).

DRUG

Cytarabine

cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)

DRUG

Hign dose Daunorubicin

Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).

Trial Locations (1)

Asan Medical Center, University of Ulsan College of Medicine, Seoul